☰

Himanshu Garg, Ph.D. - Publications

Affiliations: 
2003 North Carolina State University, Raleigh, NC 
Area:
Immunology, Veterinary Science Biology, Microbiology Biology
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Garg H, Mehmetoglu-Gurbuz T, Joshi A. Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. Scientific Reports. 10: 4017. PMID 32132648 DOI: 10.1038/S41598-020-61103-1  0.326
2019 Garg H, Mehmetoglu-Gurbuz T, Ruddy GM, Joshi A. Capsid containing virus like particle vaccine against Zika virus made from a stable cell line. Vaccine. PMID 31607605 DOI: 10.1016/J.Vaccine.2019.09.093  0.324
2019 Mehmetoglu-Gurbuz T, Joshi A, Garg H. Differential Pathogenicity of SHIV KB9 and 89.6 Env Correlates with Bystander Apoptosis Induction in CD4+ T cells. Viruses. 11. PMID 31581579 DOI: 10.3390/V11100911  0.39
2019 Palanichamy K, Joshi A, Mehmetoglu-Gurbuz T, Bravo F, Shlain M, Schiro F, Naeem Y, Garg H, Braunschweig AB. Anti-Zika Activity of a Library of Synthetic Carbohydrate Receptors. Journal of Medicinal Chemistry. PMID 30925051 DOI: 10.1021/Acs.Jmedchem.9B00142  0.368
2019 Joshi A, Punke EB, Mehmetoglu-Gurbuz T, Peralta DP, Garg H. TLR9 polymorphism correlates with immune activation, CD4 decline and plasma IP10 levels in HIV patients. Bmc Infectious Diseases. 19: 56. PMID 30651082 DOI: 10.1186/S12879-019-3697-9  0.399
2017 Joshi A, Cox EK, Sedano MJ, Punke EB, Lee RT, Maurer-Stroh S, Kaur P, Ng OT, Garg H. HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites. Virology. 512: 222-233. PMID 29020646 DOI: 10.1016/J.Virol.2017.09.026  0.412
2017 Garg H, Joshi A. Host and Viral Factors in HIV-Mediated Bystander Apoptosis. Viruses. 9. PMID 28829402 DOI: 10.3390/V9080237  0.488
2017 Joshi A, Punke EB, Sedano M, Beauchamp B, Patel R, Hossenlopp C, Alozie OK, Gupta J, Mukherjee D, Garg H. CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis. Scientific Reports. 7: 232. PMID 28331180 DOI: 10.1038/S41598-017-00192-X  0.426
2016 Garg H, Lee RT, Maurer-Stroh S, Joshi A. HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc. Virology. 493: 86-99. PMID 27017055 DOI: 10.1016/J.Virol.2016.03.010  0.455
2016 Garg H, Joshi A. A CONDITIONAL CYTOTOXIC ANTI-HIV GENE THERAPY FOR SELECTABLE CELL MODIFICATION. Human Gene Therapy. PMID 26800572 DOI: 10.1089/Hum.2015.126  0.451
2016 Joshi A, Sedano M, Beauchamp B, Punke EB, Mulla ZD, Meza A, Alozie OK, Mukherjee D, Garg H. HIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients. Journal of Immunology (Baltimore, Md. : 1950). PMID 26764036 DOI: 10.4049/Jimmunol.1501588  0.463
2014 Joshi A, Lee RT, Mohl J, Sedano M, Khong WX, Ng OT, Maurer-Stroh S, Garg H. Genetic signatures of HIV-1 envelope-mediated bystander apoptosis. The Journal of Biological Chemistry. 289: 2497-514. PMID 24265318 DOI: 10.1074/Jbc.M113.514018  0.468
2013 Garg H, Lee RT, Tek NO, Maurer-Stroh S, Joshi A. Identification of conserved motifs in the West Nile virus envelope essential for particle secretion. Bmc Microbiology. 13: 197. PMID 24007503 DOI: 10.1186/1471-2180-13-197  0.363
2013 Garg H, Joshi A, Mukherjee D. Cardiovascular complications of HIV infection and treatment. Cardiovascular & Hematological Agents in Medicinal Chemistry. 11: 58-66. PMID 22946901 DOI: 10.2174/1871525711311010010  0.403
2012 Garg H, Mohl J, Joshi A. HIV-1 induced bystander apoptosis. Viruses. 4: 3020-43. PMID 23202514 DOI: 10.3390/V4113020  0.493
2012 Garg H, Joshi A. SNAREs in HIV-1 assembly. Communicative & Integrative Biology. 5: 172-4. PMID 22808325 DOI: 10.4161/Cib.18742  0.389
2012 Nyakeriga AM, Garg H, Joshi A. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 81: 797-805. PMID 22674786 DOI: 10.1002/Cyto.A.22070  0.316
2011 Garg H, Viard M, Jacobs A, Blumenthal R. Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy. Current Topics in Medicinal Chemistry. 11: 2947-58. PMID 22044225 DOI: 10.2174/156802611798808479  0.479
2011 Joshi A, Nyakeriga AM, Ravi R, Garg H. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity. The Journal of Biological Chemistry. 286: 36404-13. PMID 21859712 DOI: 10.1074/Jbc.M111.281659  0.489
2011 Bachan S, Fantini J, Joshi A, Garg H, Mootoo DR. Synthesis, gp120 binding and anti-HIV activity of fatty acid esters of 1,1-linked disaccharides. Bioorganic & Medicinal Chemistry. 19: 4803-11. PMID 21783371 DOI: 10.1016/J.Bmc.2011.06.078  0.443
2011 Joshi A, Garg H, Ablan SD, Freed EO. Evidence of a role for soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) machinery in HIV-1 assembly and release. The Journal of Biological Chemistry. 286: 29861-71. PMID 21680744 DOI: 10.1074/Jbc.M111.241521  0.421
2011 Joshi A, Garg H, Ablan S, Freed EO, Nagashima K, Manjunath N, Shankar P. Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. Virology. 415: 95-106. PMID 21529874 DOI: 10.1016/J.Virol.2011.03.028  0.444
2011 Garg H, Joshi A, Ye C, Shankar P, Manjunath N. Single amino acid change in gp41 region of HIV-1 alters bystander apoptosis and CD4 decline in humanized mice. Virology Journal. 8: 34. PMID 21255440 DOI: 10.1186/1743-422X-8-34  0.509
2010 Loomis K, Smith B, Feng Y, Garg H, Yavlovich A, Campbell-Massa R, Dimitrov DS, Blumenthal R, Xiao X, Puri A. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Experimental and Molecular Pathology. 88: 238-49. PMID 20122924 DOI: 10.1016/J.Yexmp.2010.01.006  0.347
2010 Viard M, Garg H, Blumenthal R, Raviv Y. Alteration of Membrane Protein Function Through the Photo-Activation of the Hydrophobic Probe Iodonaphtylazide Biophysical Journal. 98. DOI: 10.1016/J.Bpj.2009.12.315  0.326
2009 Garg H, Joshi A, Blumenthal R. Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants. Aids Research and Human Retroviruses. 25: 811-7. PMID 19619009 DOI: 10.1089/Aid.2009.0010  0.49
2009 Viard M, Garg H, Blumenthal R, Raviv Y. Photo-activation of the hydrophobic probe iodonaphthylazide in cells alters membrane protein function leading to cell death. Bmc Cell Biology. 10: 21. PMID 19323821 DOI: 10.1186/1471-2121-10-21  0.359
2008 Garg H, Francella N, Tony KA, Augustine LA, Barchi JJ, Fantini J, Puri A, Mootoo DR, Blumenthal R. Glycoside analogs of β-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry Antiviral Research. 80: 54-61. PMID 18538869 DOI: 10.1016/J.Antiviral.2008.04.004  0.493
2008 Garg H, Blumenthal R. Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis Cellular and Molecular Life Sciences. 65: 3134-3144. PMID 18500445 DOI: 10.1007/S00018-008-8147-6  0.471
2008 Joshi A, Garg H, Nagashima K, Bonifacino JS, Freed EO. GGA and Arf proteins modulate retrovirus assembly and release. Molecular Cell. 30: 227-38. PMID 18439901 DOI: 10.1016/J.Molcel.2008.03.015  0.323
2008 Jacobs A, Garg H, Viard M, Raviv Y, Puri A, Blumenthal R. HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine. 26: 3026-35. PMID 18242797 DOI: 10.1016/J.Vaccine.2007.12.026  0.479
2007 Garg H, Joshi A, Freed EO, Blumenthal R. Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. The Journal of Biological Chemistry. 282: 16899-906. PMID 17416587 DOI: 10.1074/Jbc.M701701200  0.49
2006 Gallo SA, Reeves JD, Garg H, Foley B, Doms RW, Blumenthal R. Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology. 3: 90. PMID 17144914 DOI: 10.1186/1742-4690-3-90  0.467
2006 Garg H, Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. Journal of Leukocyte Biology. 79: 351-62. PMID 16330530 DOI: 10.1189/Jlb.0805430  0.495
2006 Garg H, Blumenthal R. Mutational analysis of HIV-1 gp41 mediated apoptosis and its correlation with fusion/hemifusion Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-S89  0.486
2005 Joshi A, Garg H, Tompkins MB, Tompkins WA. Different thresholds of T cell activation regulate FIV infection of CD4+CD25+ and CD4+CD25- cells. Virology. 335: 212-21. PMID 15840520 DOI: 10.1016/J.Virol.2005.02.016  0.351
2005 Joshi A, Garg H, Tompkins MB, Tompkins WA. Preferential feline immunodeficiency virus (FIV) infection of CD4+ CD25+ T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors. Journal of Virology. 79: 4965-76. PMID 15795282 DOI: 10.1128/Jvi.79.8.4965-4976.2005  0.354
2004 Garg H, Joshi A, Tompkins WA. Feline immunodeficiency virus envelope glycoprotein mediates apoptosis in activated PBMC by a mechanism dependent on gp41 function. Virology. 330: 424-36. PMID 15567436 DOI: 10.1016/J.Virol.2004.10.007  0.49
2004 Joshi A, Vahlenkamp TW, Garg H, Tompkins WA, Tompkins MB. Preferential replication of FIV in activated CD4(+)CD25(+)T cells independent of cellular proliferation. Virology. 321: 307-22. PMID 15051390 DOI: 10.1016/J.Virol.2004.01.014  0.388
2004 Garg H, Fuller FJ, Tompkins WA. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology. 321: 274-86. PMID 15051387 DOI: 10.1016/J.Virol.2004.01.006  0.471
Show low-probability matches.